China Compounding Pharmacy Market Size, Share, Trends and Forecasts 2031

Key Findings

• The China Compounding Pharmacy Market is experiencing steady growth due to increasing demand for personalized medications and patient-specific therapies.

• Rising prevalence of chronic diseases and allergies in China is accelerating the need for customized drug formulations.

• Compounding pharmacies play a critical role in addressing drug shortages and discontinued commercial medications.

• Growing awareness among healthcare professionals regarding tailored dosing solutions is strengthening market adoption.

• Technological advancements in pharmaceutical compounding equipment are improving safety and accuracy in China.

• Pediatric, geriatric, and veterinary medicine segments are driving consistent demand for compounded drugs.

• Regulatory oversight in China is shaping quality standards and compliance requirements across the industry.

• Increasing collaboration between physicians and compounding pharmacies is enhancing therapeutic outcomes.

China Compounding Pharmacy Market Size and Forecast

The China Compounding Pharmacy Market is projected to grow from USD 6.4 billion in 2025 to USD 11.9 billion by 2031, at a CAGR of 10.8% during the forecast period. Market growth is driven by rising demand for personalized healthcare solutions, increased incidence of chronic and rare diseases, and the need for alternative dosage forms. In China, aging populations and pediatric care requirements are further strengthening demand for compounded medications.

Expanding healthcare infrastructure and physician acceptance of compounding practices are supporting market expansion. With continued regulatory evolution and technological upgrades, the market is expected to maintain strong momentum through 2031.

Introduction

Compounding pharmacies specialize in preparing customized medications tailored to individual patient needs by modifying dosage, formulation, or delivery method. In China, these pharmacies serve patients who cannot be adequately treated with mass-produced drugs due to allergies, dosage limitations, or drug unavailability. Compounded medications are widely used in hormone replacement therapy, pain management, dermatology, and veterinary care.

The market is regulated to ensure safety, quality, and consistency of compounded products. As healthcare shifts toward personalization, compounding pharmacies are becoming an integral part of modern therapeutic delivery in China.

Future Outlook

By 2031, compounding pharmacies in China are expected to become more technologically advanced and clinically integrated. Digital prescription systems and automated compounding equipment will enhance accuracy and operational efficiency. Personalized medicine initiatives will further expand the role of compounded therapies across multiple medical specialties.

Regulatory clarity and standardization will improve market credibility and patient trust. With increasing emphasis on individualized care, compounding pharmacies will remain essential contributors to healthcare delivery in China.

China Compounding Pharmacy Market Trends

• Rising Demand for Personalized Medicine
  Personalized healthcare is a major trend driving the compounding pharmacy market in China. Patients increasingly require customized dosages, allergen-free formulations, and alternative drug delivery methods. Physicians are prescribing compounded medications to address unmet clinical needs where commercial drugs fall short. Advances in diagnostics are enabling more precise treatment customization. This trend reinforces the importance of compounding pharmacies in patient-centric care models.

• Growth in Hormone Replacement and Pain Management Therapies
  Compounded hormone replacement therapies are gaining popularity in China due to tailored dosing and formulation flexibility. Pain management therapies also rely heavily on compounded medications to optimize efficacy and minimize side effects. Chronic pain patients often require unique combinations or delivery formats not available commercially. Increased physician awareness is contributing to wider adoption of these therapies. This trend is significantly boosting prescription volumes for compounding pharmacies.

• Technological Advancements in Compounding Equipment
  Automation and precision equipment are transforming compounding pharmacy operations in China. Advanced mixers, automated filling systems, and digital verification tools are enhancing safety and consistency. These technologies help reduce human error and improve compliance with regulatory standards. Pharmacies investing in modern equipment gain competitive advantages in quality and scalability. This trend supports both operational efficiency and patient safety.

• Increasing Role in Addressing Drug Shortages
  Drug shortages remain a persistent challenge in China, particularly for injectables and specialty medications. Compounding pharmacies are increasingly relied upon to supply alternatives during shortages. Healthcare providers depend on these pharmacies to ensure continuity of patient care. This role has expanded the strategic importance of compounding services within healthcare systems. The trend underscores the market’s resilience and necessity.

• Expansion of Veterinary Compounding Services
  Veterinary medicine is emerging as a strong growth area for compounding pharmacies in China. Animals often require customized dosages, flavors, and formulations to ensure compliance. Commercial veterinary drugs may not meet species-specific requirements. Veterinarians are increasingly collaborating with compounding pharmacies to deliver tailored treatments. This trend is broadening the market’s end-user base.

Market Growth Drivers

• Increasing Prevalence of Chronic and Rare Diseases
  Chronic conditions such as diabetes, arthritis, and dermatological disorders are rising in China. Many patients with rare diseases require customized therapies unavailable in standardized drug formats. Compounding pharmacies offer flexible solutions that improve treatment outcomes. Physicians increasingly rely on these services for complex cases. This driver is a foundational force behind sustained market growth.

• Growing Geriatric and Pediatric Populations
  Aging populations in China often require modified dosages or alternative delivery forms due to swallowing difficulties or sensitivity to standard medications. Pediatric patients also benefit from flavoring and precise dosing offered by compounded drugs. These demographic groups are underserved by mass-produced pharmaceuticals. Compounding pharmacies effectively bridge this gap. Demographic shifts are therefore driving long-term demand.

• Shift Toward Patient-Centric Healthcare
  Healthcare systems in China are increasingly prioritizing individualized treatment approaches. Patient-centric models emphasize tailored therapies that enhance safety and adherence. Compounded medications align perfectly with this paradigm by offering customized solutions. Physicians and healthcare providers are integrating compounding services into treatment protocols. This shift is accelerating market adoption across specialties.

• Rising Awareness Among Healthcare Professionals
  Education and training initiatives are improving awareness of compounding benefits among physicians and pharmacists in China. As confidence in quality and efficacy grows, prescription rates are increasing. Professional associations are also promoting best practices and compliance standards. This growing trust is expanding market acceptance. Increased professional endorsement is strengthening industry credibility.

• Technological and Operational Improvements
  Improved compounding workflows and quality control systems are enhancing operational reliability in China. Digital prescription management and batch tracking are improving transparency. These improvements reduce risks and improve regulatory compliance. Pharmacies that adopt advanced systems are able to scale operations effectively. This driver is enabling sustainable market expansion.

Challenges in the Market

• Stringent Regulatory Compliance Requirements
  Compounding pharmacies in China operate under strict regulatory frameworks to ensure patient safety. Compliance with evolving guidelines requires continuous investment in training, equipment, and documentation. Smaller pharmacies often struggle to meet these requirements. Regulatory complexity can slow market entry and expansion. Navigating compliance remains a significant operational challenge.

• Quality Control and Safety Concerns
  Ensuring consistent quality across compounded medications is critical yet challenging. Variability in formulations and processes can pose safety risks if not properly managed. Any quality lapse can undermine trust in compounding pharmacies. Maintaining high standards requires robust quality assurance systems. Safety concerns remain a key restraint on market growth.

• Limited Awareness Among Patients
  Many patients in China remain unaware of compounding pharmacy services and their benefits. This limits direct demand and reliance on physician recommendations. Public education initiatives are still developing. Without broader patient awareness, market penetration may remain constrained. Increasing visibility is essential for long-term expansion.

• Higher Costs Compared to Commercial Drugs
  Compounded medications often cost more than mass-produced pharmaceuticals. Price sensitivity among patients can restrict adoption, especially in cost-conscious markets. Insurance reimbursement limitations further exacerbate affordability issues. Pharmacies must balance customization with cost efficiency. Pricing remains a persistent challenge.

• Operational and Workforce Constraints
  Skilled pharmacists and technicians are essential for safe compounding practices. In China, shortages of trained personnel can limit service capacity. Continuous training is necessary to keep pace with regulatory and technological changes. Workforce constraints can slow operational scaling. Addressing talent gaps is crucial for sustained growth.

China Compounding Pharmacy Market Segmentation

By Product Type

• Oral Compounded Medications

• Topical Compounded Medications

• Injectable Compounded Medications

• Others

By Therapeutic Area

• Pain Management

• Hormone Replacement Therapy

• Dermatology

• Specialty and Rare Diseases

• Veterinary Medicine

By End-User

• Hospitals

• Clinics

• Home Care Settings

• Veterinary Clinics

Leading Key Players

• Fagron N.V.

• PCCA (Professional Compounding Centers of America)

• Capsugel (Lonza Group)

• B. Braun Melsungen AG

• Fresenius Kabi AG

• ImprimisRx

• Leiter’s Pharmacy

• QuVa Pharma, Inc.

• Aequus Pharmaceuticals

• Humco Holding Group

Recent Developments

• Fagron N.V. expanded its compounding ingredient portfolio in China.

• PCCA launched advanced training programs for compounding pharmacists in China.

• ImprimisRx introduced new ophthalmic compounded therapies in China.

• QuVa Pharma, Inc. invested in sterile compounding facilities to improve supply reliability in China.

• Fresenius Kabi AG strengthened partnerships with hospitals for compounded injectable solutions in China.

This Market Report Will Answer the Following Questions

1. What is the projected size and CAGR of the China Compounding Pharmacy Market by 2031?

2. Which therapeutic areas are driving the highest demand in China?

3. How is personalized medicine influencing compounding pharmacy adoption?

4. What regulatory and operational challenges affect market growth in China?

5. Who are the leading players shaping the China compounding pharmacy landscape?